CD27 is a type I glycoprotein expressed on some B cells and the majority of T cells, and is a member of the tumor necrosis factor (TNF) receptor family, with unique cysteinerich motifs.
An Overview of CD27
CD27 is a type I transmembrane glycoprotein made of 260 amino acids. There is a hydrophobic signal peptide at its N-terminal, composed by 20 amino acids. Besides that, a mature extracellular domain consists of 171 amino acid residues, a hydrophobic transmembrane domain consists of 21 amino acid residues and a cytoplasmic functional area consists of 48 amino acid residues are located. CD27 is one of the members of the NGFR/TNFR superfamily, and is expressed in a large number of peripheral T cells, medullary thymus B cells and some NK cells. CD27 plays an important role in the activation of T cells, the differentiation of CTI and cytotoxic function, the regulation of B cell differentiation and the regulation of NK cytotoxicity.
Agonist of CD27
It was found that when CV-l/EBNA with apparent CD27 ligand (CD27L) were added to the suboptimal density PHA, CD27L can enhance the colonization of T cells. But in the absence of PHA, CD27L was not used for T cell colonization. It can be observed that PHA can promote the binding of CD27 to its ligand CD27L and stimulate the colonization of T cells.
CD27 and Diseases
CD27 plays an important role in immunomodulation. Further study on the molecular energy of CD27 will help to elucidate the process of differentiation and development of T cells. High expression of CD27 was found in some types of non-Hodgkin's lymphoma and B lymphoblastic leukemia/lymphoma. In general, CD27 plays a role in the development of these tumours, while whether it exists in the self-stimulator system remains to be studied.
Pan Jianping. A. (1996). Research Progress of CD27 molecule. Foreign medicine. 1;8-11
Qin Yong et al. A. (2013). Advances in the study of the relationship between CD27, CD70, body immunity and tumor Development. Chinese Journal of Immunology. 29(10);1115-1118